OrthoPediatrics projects 2024 revenue to be in the range of $197 million to $200 million, including revenue contribution from Boston O&P and representing 32% to 34% growth compared to full year 2023 preliminary unaudited net revenue. The acquisition is expected to be accretive to OrthoPediatrics adjusted EBITDA in 2024 and accretive to revenue growth in 2025, following the completion of integration activities. Boston O&P’s recent annual historical revenue is approximately $25 million. Boston O&P was a customer of OrthoPediatrics, purchasing the MD Orthopedics clubfoot specialty brace as well as a supplier to OrthoPediatrics, manufacturing the recently launched DF2 brace.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023
- OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics
- OrthoPediatrics price target raised to $39 from $35 at Truist
- OrthoPediatrics price target lowered to $50 from $60 at JMP Securities
- OrthoPediatrics announces launch of specialty bracing division